{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT05054803",
      "OrgStudyIdInfo": {
        "OrgStudyId": "BST-SCI-02"
      },
      "Organization": {
        "OrgFullName": "Banc de Sang i Teixits",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury",
      "OfficialTitle": "A Phase I/II, Randomized, Double-blind, Placebo-controlled, Parallel, 2-arms Clinical Trial to Assess the Safety and Efficacy of Intrathecal Administration of WJ-MSC in Chronic Traumatic Cervical Incomplete Spinal Cord Injury"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 13, 2021",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2023",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2025",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 14, 2021",
      "StudyFirstSubmitQCDate": "September 14, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 23, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "December 3, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 20, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Banc de Sang i Teixits",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Institut Guttmann",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Academic Research Organization (ARO) - VHIR",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a double-blind, randomized, placebo-controlled, multicenter clinical trial in which 18 patients affected with chronic traumatic incomplete cervical spinal cord injury will be randomized to either the active treatment (2 doses of intrathecal WJ-MSC 3 months apart) or to placebo (2 intrathecal infusions, 3 months apart). Thereafter, patients will be followed-up for 12 months for safety and efficacy assessment.",
      "DetailedDescription": "Double-blind, randomized, placebo-controlled, multicenter clinical trial that will include 18 patients affected with chronic traumatic incomplete cervical spinal cord injury who will be randomized 2:1, stratified by center, to one of the 2 treatment arms of the study: WJ-MSC / WJ-MSC (at a dose of 1E6 ± 30% live cells / Kg of weight) or Placebo / placebo. Medication will be administered intrathecally at day 1 and at 3 months. The main objective of the trial is to assess safety at 12-month follow-up. Secondary objectives include the evaluation of efficacy through clinical response, electrophysiological changes, questionnaires of functionality and quality of life, as well as the presence of anti-HLA antibodies and donor cellularity in the cerebrospinal fluid."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Spinal Cord Injury Cervical"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "spinal cord injury",
          "Mesenchymal stromal cells",
          "Wharton jelly",
          "Cell therapy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Double-blind, randomized, placebo-controlled, 2-arms, multicenter clinical trial",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignMaskingDescription": "Active treatment and placebo will be released using the same syringe and blinded in a way that it is no possible to distinguish one to the other.",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "18",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "WJ-MSC (XCEL-UMC-BETA)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Pre-filled syringe with 4 ± 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: WJ-MSC (XCEL-UMC-BETA)"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Pre-filled syringe with 4 ± 1 mL containing a balanced saline solution supplemented with human albumin",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "WJ-MSC (XCEL-UMC-BETA)",
            "InterventionDescription": "Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "WJ-MSC (XCEL-UMC-BETA)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Tested product"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo",
            "InterventionDescription": "Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of adverse events",
            "PrimaryOutcomeDescription": "Adverse events",
            "PrimaryOutcomeTimeFrame": "At 12 month follow-up"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "American Spinal Injury Association (ASIA) impairment scale",
            "SecondaryOutcomeDescription": "Changes in ASIA score with respect to baseline value as detailed at https://asia-spinalinjury.org/international-standards-neurological-classification-sci-isncsci-worksheet/",
            "SecondaryOutcomeTimeFrame": "At 1, 3, 4, 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Motor evoked potentials",
            "SecondaryOutcomeDescription": "Changes in motor evoked potentials score with respect to baseline value. Higher scores mean a better outcome",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Somatosensory evoked potentials",
            "SecondaryOutcomeDescription": "Changes in somatosensory evoked potentials score with respect to baseline value. Higher scores mean a better outcome",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Electrical pain threshold perception",
            "SecondaryOutcomeDescription": "Changes in electrical pain threshold perception score with respect to baseline. Lower scores mean a better outcome",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Handgrip Strength",
            "SecondaryOutcomeDescription": "Will be assessed using a dynamometer. Changes in the score with respect to baseline values. Higher scores mean a better outcome",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Walking index for spinal cord injury (WISCI II)",
            "SecondaryOutcomeDescription": "Changes in the walk test WISCIII score with respect to baseline value. The score ranges from 0 (most severe impairment) to 20 (least severe impairment)",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Numerical scale for neuropathic pain assessment",
            "SecondaryOutcomeDescription": "Changes in the numerical scale for neuropathic pain score with respect to baseline value. Score ranges from 0 (no pain) to 10 (unbearable pain)",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Modified Ashworth scale for spasticity",
            "SecondaryOutcomeDescription": "Changes in the modified Ashworth scale score with respect to baseline value. It is a 5 point numerical scale that graded spasticity from 0 to 4, with 0 being no resistance and 4 being a limb rigid in flexion or extension, and includes a 1+ value.",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Spinal Cord Independence Measure III (SCIM III)",
            "SecondaryOutcomeDescription": "Changes in the SCIM III scale score with respect to baseline value. Score ranges from 0 to 20 with higher scores meaning better outcome.",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "World Health Organization Quality of life questionnaire (WHOQOL-BREF)",
            "SecondaryOutcomeDescription": "Changes in the WHOQOL-BREF score with respect to baseline value. It contains contains 26 questions each punctuated from 1 to 5 and assesses the individual's overall perception of quality of life (1 to 5), overall perception of their health (1 to 5) and 4 domains of physical health, psychological, social relationships, environment (0-100 each domain). higher scores denote higher quality of life.",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Psychological general well-being index (PGWBI)",
            "SecondaryOutcomeDescription": "Changes in the PGWBI score with respect to baseline value. Score ranges from 0 to 132, with higher scores meaning a better outcome.",
            "SecondaryOutcomeTimeFrame": "At 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Hospital Anxiety and Depression Scale (HADS)",
            "SecondaryOutcomeDescription": "Changes in the HADS score with respect to baseline value. This is a 14-item self-administered questionnaire containing 2 subscales (one for anxiety and one for depression), with a score range of each subscale from 0-21. Higher score indicates higher anxiety and depression.",
            "SecondaryOutcomeTimeFrame": "At 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Community Integration Questionaire (CIQ-IG)",
            "SecondaryOutcomeDescription": "Changes in the CIQ-IG score with respect to baseline value. Score ranges from 0 to 25, with higher scores meaning a better outcome.",
            "SecondaryOutcomeTimeFrame": "At 12 month follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "AntiHLA antibodies in cerebrospinal fluid (CSF)",
            "SecondaryOutcomeDescription": "Presence or absence of antiHLA antibodies in the CSF after two WJ-MSC infusions",
            "SecondaryOutcomeTimeFrame": "At 7 days and at 1 month follow-up after each infusion"
          },
          {
            "SecondaryOutcomeMeasure": "Detection of donor cells in CSF",
            "SecondaryOutcomeDescription": "Short tandem repeat (STR) analysis to detect permanence of donor cellularity (WJ-MsC) in the CSF",
            "SecondaryOutcomeTimeFrame": "At 7 days after each infusion"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSingle spinal cord injury lesion caused by trauma\nAffected cord segments between C1 and T1, confirmed by magnetic resonance\nIncomplete lesion (ASIA B, C or D)\nChronic disease state (between 1 and 5 years after the injury)\nPatients from 18 to 70 years of age, both sexes\nLife expectancy > 2 years\nResidence near the center during study participation and confidence that the patient will attend the follow-up visits\nGiven informed consent in writing\nPatient is able to understand the study and its procedures\n\nExclusion Criteria:\n\nMechanic ventilation\nPenetrating trauma affecting the spinal cord\nPregnant woman or without proper anticonceptive measures according to the investigator, or breath feeding\nPlanned spinal surgery within subsequent 12 month after entering the trial\nNeurodegenerative diseases\nSignificant abnormal laboratory tests that contraindicates patient's participation in the study\nNeoplasia within the previous 5 years, or without complete remission\nPatient with communication difficulties\nSimultaneous participation in another clinical trial or treated with an investigational medicinal product the previous 30 days, that could interfere in the results of the study\nPrevious treatment with and advanced Therapy Medicinal Product (cell therapy)\nContraindication for lumbar punction\nContraindication or inability to follow a rehabilitation program\nOther pathologic conditions or circumstances that difficult participation in the study according to medical criteria\nThe patient does not accept to be followed-up for a period that could exceed the clinical trial length",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Ruth COLL, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+34935573500",
            "CentralContactPhoneExt": "6707",
            "CentralContactEMail": "rucoll@bst.cat"
          },
          {
            "CentralContactName": "Joaquin DELGADILLO, MD, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+34935573500",
            "CentralContactPhoneExt": "6643",
            "CentralContactEMail": "jadelgadillo@bst.cat"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Joan VIDAL, MD, PhD",
            "OverallOfficialAffiliation": "Institut Guttmann",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital de Neurorehabilitació Institut Guttmann",
            "LocationStatus": "Recruiting",
            "LocationCity": "Badalona",
            "LocationState": "Barcelona",
            "LocationZip": "08916",
            "LocationCountry": "Spain",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Joan Vidal, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+34 934977700",
                  "LocationContactEMail": "jvidal@guttmann.com"
                },
                {
                  "LocationContactName": "Jesús Benito, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+34 934977700",
                  "LocationContactEMail": "jbenito@guttmann.com"
                },
                {
                  "LocationContactName": "Joan Vidal, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                },
                {
                  "LocationContactName": "Jesús Benito, MD, PhD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Hatice Kumru Cam, MD, PhD",
                  "LocationContactRole": "Sub-Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "Complexo Hospitalario Universitario A Coruña (CHUAC)",
            "LocationStatus": "Not yet recruiting",
            "LocationCity": "A Coruña",
            "LocationZip": "15006",
            "LocationCountry": "Spain",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Antonio Montoto, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+34 981 178117",
                  "LocationContactEMail": "antonio.montoto.marques@sergas.es"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "32981857",
            "ReferenceType": "background",
            "ReferenceCitation": "Albu S, Kumru H, Coll R, Vives J, Vallés M, Benito-Penalva J, Rodríguez L, Codinach M, Hernández J, Navarro X, Vidal J. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146-156. doi: 10.1016/j.jcyt.2020.08.008. Epub 2020 Sep 25."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Blood and tissue bank of Catalonia, cell producer and sponsor of the trial",
            "SeeAlsoLinkURL": "https://www.bancsang.net"
          },
          {
            "SeeAlsoLinkLabel": "Hospital specialized in spinal cord injury",
            "SeeAlsoLinkURL": "https://www.guttmann.com/"
          },
          {
            "SeeAlsoLinkLabel": "Hospital specialized in spinal cord injury",
            "SeeAlsoLinkURL": "https://xxicoruna.sergas.gal/Paxinas/web.aspx?tipo=paxtxt&idContido=595&idLista=4"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000013119",
            "ConditionMeshTerm": "Spinal Cord Injuries"
          },
          {
            "ConditionMeshId": "D000014947",
            "ConditionMeshTerm": "Wounds and Injuries"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000013118",
            "ConditionAncestorTerm": "Spinal Cord Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000020196",
            "ConditionAncestorTerm": "Trauma, Nervous System"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M15068",
            "ConditionBrowseLeafName": "Spinal Cord Injuries",
            "ConditionBrowseLeafAsFound": "Spinal Cord Injury",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16837",
            "ConditionBrowseLeafName": "Wounds and Injuries",
            "ConditionBrowseLeafAsFound": "Injury",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M15067",
            "ConditionBrowseLeafName": "Spinal Cord Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21176",
            "ConditionBrowseLeafName": "Trauma, Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC26",
            "ConditionBrowseBranchName": "Wounds and Injuries"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}